Litcius/Paper detail

LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

Erica L. Mayer, M.I. Gnant, Angela DeMichele, Miguel Martín, Harold J. Burstein, Aleix Prat, Gábor Rubovszky, Kathy D. Miller, Georg Pfeiler, Eric P. Winer, Nicholas Zdenkowski, D. Mark Anderson, Zbigniew Nowecki, Sibylle Loibl, Hannes Fohler, Otto Metzger, Debora Fumagalli, Kathy Puyana Theall, Christian Fesl, Amylou C. Dueck

2020Annals of Oncology29 citationsDOIOpen Access PDF

Topics & Concepts

MedicineHazard ratioBreast cancerPalbociclibInternal medicineOncologyAdjuvantCancerInterim analysisRandomized controlled trialConfidence intervalMetastatic breast cancerAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchPeptidase Inhibition and Analysis
LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer | Litcius